Balancing Patient Preference and Access Challenges in Oral vs Injectable ADT in Prostate Cancer

In ‘Balancing Patient Preference and Access Challenges in Oral vs Injectable ADT in Prostate Cancer,’ our multidisciplinary panelists delve into the following questions:

1. How often do patient preferences, such as avoiding injections or reducing office visits, influence your ADT treatment decisions for patients with advanced prostate cancer?
   1. How do you resolve differences between your and your patient’s preference for oral versus injectable ADT when finalizing treatment strategy?
2. What access-related challenges have you faced when prescribing ADT therapies for patients with advanced prostate cancer?
   1. How do those challenges influence treatment selection? What suggestions do you have to mitigate these challenges?

Led by the moderator, the expert urologists and medical oncologists explores how patient preference increasingly shapes decisions between oral and injectable androgen deprivation therapy (ADT). Panelists highlight that oral options can improve acceptance of ADT by giving patients a greater sense of control, reversibility, and autonomy—particularly for those hesitant to initiate therapy or concerned about side effects. Practical considerations such as injection-site reactions, anticoagulation use, frailty, and quality-of-life concerns further influence agent selection. The discussion also notes that recent Medicare Part D reforms and improved payer coverage have significantly reduced access barriers, supporting broader adoption of oral ADT in appropriate patients.

Our next episode, ‘Practical Advice for Managing Advanced Prostate Cancer Care,’ further explores advanced prostate cancer, sharing practical advice on setting up an effective advanced prostate cancer practice, emphasizing multidisciplinary care, standardized templates, and systematic monitoring. Structured workflows help ensure comprehensive, consistent, and high-quality patient management.